Articles by Dr. Yuna Park
Sun Pharma Organon Partnership to Expand Access to Key Medicines
Sun Pharma has announced a strategic partnership with Organon to commercialize five of Organon's established products across India. This collaboration aims to leverage Sun Pharma's extensive network to improve patient access to vital treatments.
FDA Scrutiny Post-Market Data: Impact on Pharma Investment Strategies
This article examines the implications of FDA scrutiny on post-market data and its influence on pharmaceutical investment strategies and drug development.
EMA Conditional Marketing Authorizations: Evolving Framework & PRAC Safety Insights
This article delves into the evolving framework of EMA Conditional Marketing Authorizations and highlights PRAC's safety insights for drug XYZ in cancer therapy.
Decentralized Clinical Trials in LATAM: Growth, Challenges & Regulatory Insights
This article delves into the rise of decentralized clinical trials in LATAM, highlighting key growth factors, challenges faced, and essential regulatory insights.
Apotex Receives First Canadian Health Canada Approval for Generic Ozempic (Semaglutide) Alternative
Apotex becomes first Canadian pharmaceutical company to receive Health Canada approval for Apo-Semaglutide Injection, a generic equivalent of Ozempic.
NMPA Accelerated Approval Pathway: Impact on Innovative Drug Market Entry in China
The NMPA Accelerated Approval Pathway significantly enhances the speed of innovative drug market entry in China, particularly for critical cancer treatments.
EMA Conditional Marketing Authorization: Linvoseltamab for RRMM in EU
Linvoseltamab has received EMA's Conditional Marketing Authorization for treating relapsed/refractory multiple myeloma, offering new hope for patients in the EU.
Alzheimer's Clinical Trial Failures: Insights from Semaglutide & Posdinemab FDA Trials
This article delves into the recent failures of Alzheimer's clinical trials involving Semaglutide and Posdinemab, highlighting key insights and future directions.
EMA Conditional Marketing Authorization: Oncology Approvals & EU Patient Access
This article delves into the EMA's Conditional Marketing Authorization process, focusing on oncology drug approvals and their impact on patient access in the EU.
Pandemic Trial Networks Repurposed: Africa’s COVID-19 Legacy in Clinical Research
This article examines the impact of Africa's COVID-19 pandemic trial networks on future clinical research, highlighting innovative strategies and drug development.
FDA Accelerated Approval Pathway: Impact on Oncology Drug Development & Market Access 2026
This article examines the FDA Accelerated Approval Pathway and its significant influence on the development and market access of oncology drugs by 2026.
EMA Conditional Marketing Authorizations: What You Need to Know
Explore the key aspects of EMA Conditional Marketing Authorizations, focusing on drug XYZ for ABC treatment, and understand its implications for the industry.
ANVISA Risk-Based Inspection: What You Need to Know About Brazil's New Compliance System
Learn about Brazil's new compliance system, ANVISA's Risk-Based Inspection, and its impact on pharmaceutical safety and market access.
TGA Updates Comprehensive Regulatory Framework for Implantable Medical Devices in Australia
Australia's TGA provides updated guidance on implantable medical device regulations, covering manufacturing, application processes, and market authorization requirements.
Pembrolizumab Combinations Mexico: COFEPRIS Market Access & Clinical Insights
Discover the latest on Pembrolizumab combinations in Mexico, including COFEPRIS market access and vital clinical insights for enhanced cancer therapies.
BioMarin Completes $3 Billion Acquisition of Amicus Therapeutics, Expands Rare Disease Portfolio with Galafold and Pompe Therapies
BioMarin's acquisition of Amicus adds globally approved Galafold for Fabry disease and POMBILITI/OPFOLDA combination for Pompe disease to its rare disease pipeline.
WuXi Biologics Chengdu Microbial Manufacturing Site Reaches Structural Completion, Targets 2026 GMP Production
WuXi Biologics announces structural completion of its Chengdu microbial manufacturing facility with key equipment arrival, targeting GMP production by end 2026.
Daewoong Pharmaceutical NABOTA Master Class Highlights PrabotulinumtoxinA Safety for High-Dose Treatments
Daewoong Pharmaceutical hosted 74 healthcare professionals from 13 countries for NABOTA Master Class, emphasizing PrabotulinumtoxinA safety protocols.
Spinogenix Launches Phase 2b/3 CLARITY Trial of SPG601 for Fragile X Syndrome Treatment
Spinogenix initiates CLARITY Phase 2b/3 trial testing SPG601, a first-in-class oral therapy targeting BK channels for Fragile X Syndrome in male patients.
SFDA Acceptance of FDA Approvals: What You Need to Know
Discover how the SFDA's acceptance of FDA drug approvals impacts the availability of diabetes medications in your region and what it means for patients.